Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > ATM & Options

<< Previous

Bullboard Posts

Next >>

Post by SABBOBCATon Mar 13, 2023 10:36am

128 Views

Post# 35334623

ATM & Options

I wonder if THTX utilized the ATM in Q1 and how that could be perceived as a conflict of interest given the annual option grants were set at such a low price?

Considering how low the volumes have been, if Management tried to raise funds with the ATM in any meaningful size, it would have likely put a cap on any price appreciation. Is that what happened? Who knows? but if it was, hold onto your hats, because that Pomerantz Law guy could be back with a vengence! Yikes!

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects